Analysts expect STAAR Surgical Company (NASDAQ:STAA) to announce $0.03 earnings per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have issued estimates for STAAR Surgical’s earnings. STAAR Surgical posted earnings of $0.02 per share in the same quarter last year, which suggests a positive year over year growth rate of 50%. The firm is expected to issue its next earnings report on Thursday, March 1st.
According to Zacks, analysts expect that STAAR Surgical will report full-year earnings of ($0.02) per share for the current year, with EPS estimates ranging from ($0.06) to $0.02. For the next financial year, analysts expect that the company will report earnings of $0.17 per share, with EPS estimates ranging from $0.15 to $0.19. Zacks Investment Research’s earnings per share calculations are an average based on a survey of analysts that that provide coverage for STAAR Surgical.
A number of research analysts have commented on STAA shares. Canaccord Genuity restated a “buy” rating and set a $15.00 price target on shares of STAAR Surgical in a research note on Sunday, October 8th. Zacks Investment Research upgraded STAAR Surgical from a “hold” rating to a “buy” rating and set a $12.00 price target on the stock in a research note on Saturday, September 23rd. Benchmark restated a “buy” rating and set a $21.00 price target on shares of STAAR Surgical in a research note on Monday, November 20th. TheStreet upgraded STAAR Surgical from a “d+” rating to a “c” rating in a research note on Tuesday, August 15th. Finally, BidaskClub upgraded STAAR Surgical from a “sell” rating to a “hold” rating in a research note on Saturday, August 19th. Two equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. STAAR Surgical currently has a consensus rating of “Buy” and a consensus target price of $17.67.
In other news, VP Keith Holliday sold 6,000 shares of the stock in a transaction on Tuesday, November 21st. The stock was sold at an average price of $16.65, for a total value of $99,900.00. Following the sale, the vice president now directly owns 45,969 shares in the company, valued at $765,383.85. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 5.60% of the stock is currently owned by company insiders.
Several hedge funds and other institutional investors have recently made changes to their positions in the company. California Public Employees Retirement System raised its stake in shares of STAAR Surgical by 8.7% in the third quarter. California Public Employees Retirement System now owns 48,711 shares of the medical instruments supplier’s stock valued at $606,000 after acquiring an additional 3,911 shares in the last quarter. Wells Fargo & Company MN increased its holdings in STAAR Surgical by 22.9% in the third quarter. Wells Fargo & Company MN now owns 65,055 shares of the medical instruments supplier’s stock valued at $810,000 after buying an additional 12,143 shares during the last quarter. Citadel Advisors LLC purchased a new position in STAAR Surgical in the third quarter valued at $172,000. Trexquant Investment LP increased its holdings in STAAR Surgical by 79.4% in the third quarter. Trexquant Investment LP now owns 19,716 shares of the medical instruments supplier’s stock valued at $245,000 after buying an additional 8,727 shares during the last quarter. Finally, Quantum Capital Management purchased a new position in STAAR Surgical in the third quarter valued at $710,000. Institutional investors and hedge funds own 77.73% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This story was first reported by American Banking News and is the property of of American Banking News. If you are viewing this story on another publication, it was illegally stolen and reposted in violation of US & international copyright legislation. The correct version of this story can be read at https://www.americanbankingnews.com/2017/12/07/staar-surgical-company-staa-expected-to-announce-earnings-of-0-03-per-share.html.
About STAAR Surgical
STAAR Surgical Company designs, develops, manufactures and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. It operates in the ophthalmic surgical market segment. Its principal products are intraocular lenses used in cataract surgery and implantable collamer lenses used in refractive surgery.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for STAAR Surgical Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STAAR Surgical Company and related companies with MarketBeat.com's FREE daily email newsletter.